| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Tumor Immunology Program, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a
member of the tumor necrosis factor family and has recently been shown
to exert tumoricidal activity in vivo in the absence of any
observable toxicity. The signaling pathways triggered by TRAIL
stimulation and the mechanisms involved in resistance against
TRAIL-mediated apoptosis are still poorly defined. We show here that
TRAIL-induced apoptosis involves late dissipation of mitochondrial
membrane potential (
m) and cytochrome c
release. These events follow activation of caspase-8 and caspase-3 and
induction of DNA fragmentation. In addition, caspase-8-deficient cells
are resistant against TRAIL-induced apoptosis, and inhibition of
caspase-8 but not caspase-9 prevents mitochondrial permeability
transition and apoptosis. In contrast, various Bcl-2- or
Bcl-xL-overexpressing tumor cell lines are sensitive to
TRAIL-induced apoptosis; however, they show a delay in TRAIL-induced
mitochondrial permeability transition compared with control
transfectants. This indicates that TRAIL-induced apoptosis depends on
caspase-8 activation rather than on the disruption of mitochondrial
integrity. Because most chemotherapeutic drugs used in the treatment of
malignancies lead to apoptosis primarily by engagement of the
mitochondrial proapoptotic machinery, we tested whether drug-resistant
tumor cells retain sensitivity for TRAIL-induced apoptosis. Tumor cells
overexpressing Bcl-2 or Bcl-xL become resistant to
apoptosis induced by the chemotherapeutic drug etoposide. However,
these cells are not protected or are only marginally protected against
TRAIL-induced apoptosis. Thus, TRAIL may still kill tumors that have
acquired resistance to chemotherapeutic drugs by overexpression of
Bcl-2 or Bcl-xL. These data will influence future treatment
strategies involving TRAIL.
This article has been cited by other articles:
![]() |
U. M. Schneiders, L. Schyschka, A. Rudy, and A. M. Vollmar BH3-only proteins Mcl-1 and Bim as well as endonuclease G are targeted in spongistatin 1-induced apoptosis in breast cancer cells Mol. Cancer Ther., October 1, 2009; 8(10): 2914 - 2925. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Jursik, M. Prchal, R. Grillari-Voglauer, K. Drbal, E. Fuertbauer, H. Jungfer, W. H. Albert, E. Steinhuber, T. Hemetsberger, J. Grillari, et al. Large-Scale Production and Characterization of Novel CD4+ Cytotoxic T Cells with Broad Tumor Specificity for Immunotherapy Mol. Cancer Res., March 1, 2009; 7(3): 339 - 353. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Fakler, S. Loeder, M. Vogler, K. Schneider, I. Jeremias, K.-M. Debatin, and S. Fulda Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance Blood, February 19, 2009; 113(8): 1710 - 1722. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Wang, T. Chen, N. Zhang, M. Yang, B. Li, X. Lu, X. Cao, and C. Ling Melittin, a Major Component of Bee Venom, Sensitizes Human Hepatocellular Carcinoma Cells to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis by Activating CaMKII-TAK1-JNK/p38 and Inhibiting I{kappa}B{alpha} Kinase-NF{kappa}B J. Biol. Chem., February 6, 2009; 284(6): 3804 - 3813. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Chetoui, K. Sylla, J.-V. Gagnon-Houde, C. Alcaide-Loridan, D. Charron, R. Al-Daccak, and F. Aoudjit Down-Regulation of Mcl-1 by Small Interfering RNA Sensitizes Resistant Melanoma Cells to Fas-Mediated Apoptosis Mol. Cancer Res., January 1, 2008; 6(1): 42 - 52. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. K. Rowinsky Targeted Induction of Apoptosis in Cancer Management: The Emerging Role of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Activating Agents J. Clin. Oncol., December 20, 2005; 23(36): 9394 - 9407. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Wang, J. Sampath, S. Fukuda, and L. M. Pelus Disruption of the Inhibitor of Apoptosis Protein Survivin Sensitizes Bcr-abl-Positive Cells to STI571-Induced Apoptosis Cancer Res., September 15, 2005; 65(18): 8224 - 8232. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Shiraishi, T. Yoshida, S. Nakata, M. Horinaka, M. Wakada, Y. Mizutani, T. Miki, and T. Sakai Tunicamycin Enhances Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Human Prostate Cancer Cells Cancer Res., July 15, 2005; 65(14): 6364 - 6370. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Baumann, A. Dostert, N. Novac, A. Bauer, W. Schmid, S. C. Fas, A. Krueger, T. Heinzel, S. Kirchhoff, G. Schutz, et al. Glucocorticoids inhibit activation-induced cell death (AICD) via direct DNA-dependent repression of the CD95 ligand gene by a glucocorticoid receptor dimer Blood, July 15, 2005; 106(2): 617 - 625. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Dicker, A. P. Kater, T. Fukuda, and T. J. Kipps Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells Blood, April 15, 2005; 105(8): 3193 - 3198. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. A. Sinicrope, R. C. Penington, and X. M. Tang Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis Is Inhibited by Bcl-2 but Restored by the Small Molecule Bcl-2 Inhibitor, HA 14-1, in Human Colon Cancer Cells Clin. Cancer Res., December 15, 2004; 10(24): 8284 - 8292. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Liu, P. Yue, Z. Zhou, F. R. Khuri, and S.-Y. Sun Death Receptor Regulation and Celecoxib-Induced Apoptosis in Human Lung Cancer Cells J Natl Cancer Inst, December 1, 2004; 96(23): 1769 - 1780. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Izeradjene, L. Douglas, A. B. Delaney, and J. A. Houghton Casein Kinase I Attenuates Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by Regulating the Recruitment of Fas-Associated Death Domain and Procaspase-8 to the Death-Inducing Signaling Complex Cancer Res., November 1, 2004; 64(21): 8036 - 8044. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Izeradjene, L. Douglas, A. Delaney, and J. A. Houghton Influence of Casein Kinase II in Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Human Rhabdomyosarcoma Cells Clin. Cancer Res., October 1, 2004; 10(19): 6650 - 6660. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Sonnemann, V. Gekeler, A. Sagrauske, C. Muller, H.-P. Hofmann, and J. F. Beck Down-regulation of protein kinase C{eta} potentiates the cytotoxic effects of exogenous tumor necrosis factor-related apoptosis-inducing ligand in PC-3 prostate cancer cells Mol. Cancer Ther., July 1, 2004; 3(7): 773 - 781. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ballestrero, A. Nencioni, D. Boy, I. Rocco, A. Garuti, G. S. Mela, L. Van Parijs, P. Brossart, S. Wesselborg, and F. Patrone Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Cooperates with Anticancer Drugs to Overcome Chemoresistance in Antiapoptotic Bcl-2 Family Members Expressing Jurkat Cells Clin. Cancer Res., February 15, 2004; 10(4): 1463 - 1470. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. Hayward, J. S. Macpherson, J. Cummings, B. P. Monia, J. F. Smyth, and D. I. Jodrell Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect Mol. Cancer Ther., February 1, 2004; 3(2): 169 - 178. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. M. Dirsch, I. M. Muller, S. T. Eichhorst, G. R. Pettit, Y. Kamano, M. Inoue, J.-P. Xu, Y. Ichihara, G. Wanner, and A. M. Vollmar Cephalostatin 1 Selectively Triggers the Release of Smac/DIABLO and Subsequent Apoptosis That Is Characterized by an Increased Density of the Mitochondrial Matrix Cancer Res., December 15, 2003; 63(24): 8869 - 8876. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Liao, L. Zhang, J. B. Thrasher, J. Du, and B. Li Glycogen synthase kinase-3{beta} suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer Mol. Cancer Ther., November 1, 2003; 2(11): 1215 - 1222. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Chawla-Sarkar, J. A. Bauer, J. A. Lupica, B. H. Morrison, Z. Tang, R. K. Oates, A. Almasan, J. A. DiDonato, E. C. Borden, and D. J. Lindner Suppression of NF-{kappa}B Survival Signaling by Nitrosylcobalamin Sensitizes Neoplasms to the Anti-tumor Effects of Apo2L/TRAIL J. Biol. Chem., October 10, 2003; 278(41): 39461 - 39469. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ruiz-Ruiz, G. Robledo, E. Cano, J. M. Redondo, and A. Lopez-Rivas Characterization of p53-mediated Up-regulation of CD95 Gene Expression upon Genotoxic Treatment in Human Breast Tumor Cells J. Biol. Chem., August 22, 2003; 278(34): 31667 - 31675. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. Hayward, J. S. Macpherson, J. Cummings, B. P. Monia, J. F. Smyth, and D. I. Jodrell Antisense Bcl-xl Down-Regulation Switches the Response to Topoisomerase I Inhibition from Senescence to Apoptosis in Colorectal Cancer Cells, Enhancing Global Cytotoxicity Clin. Cancer Res., July 1, 2003; 9(7): 2856 - 2865. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kandasamy, S. M. Srinivasula, E. S. Alnemri, C. B. Thompson, S. J. Korsmeyer, J. L. Bryant, and R. K. Srivastava Involvement of Proapoptotic Molecules Bax and Bak in Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-induced Mitochondrial Disruption and Apoptosis: Differential Regulation of Cytochrome c and Smac/DIABLO Release Cancer Res., April 1, 2003; 63(7): 1712 - 1721. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Hietakangas, M. Poukkula, K. M. Heiskanen, J. T. Karvinen, L. Sistonen, and J. E. Eriksson Erythroid Differentiation Sensitizes K562 Leukemia Cells to TRAIL-Induced Apoptosis by Downregulation of c-FLIP Mol. Cell. Biol., February 15, 2003; 23(4): 1278 - 1291. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Leverkus, M. R. Sprick, T. Wachter, T. Mengling, B. Baumann, E. Serfling, E.-B. Brocker, M. Goebeler, M. Neumann, and H. Walczak Proteasome Inhibition Results in TRAIL Sensitization of Primary Keratinocytes by Removing the Resistance-Mediating Block of Effector Caspase Maturation Mol. Cell. Biol., February 1, 2003; 23(3): 777 - 790. [Abstract] [Full Text] |
||||
![]() |
A. B. Werner, E. de Vries, S. W. G. Tait, I. Bontjer, and J. Borst TRAIL Receptor and CD95 Signal to Mitochondria via FADD, Caspase-8/10, Bid, and Bax but Differentially Regulate Events Downstream from Truncated Bid J. Biol. Chem., October 18, 2002; 277(43): 40760 - 40767. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Javelaud and F. Besancon Inactivation of p21WAF1Sensitizes Cells to Apoptosis via an Increase of Both p14ARF and p53 Levels and an Alteration of the Bax/Bcl-2 Ratio J. Biol. Chem., September 27, 2002; 277(40): 37949 - 37954. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Tang, Y. J. Sun, E. Half, M. T. Kuo, and F. Sinicrope Cyclooxygenase-2 Overexpression Inhibits Death Receptor 5 Expression and Confers Resistance to Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis in Human Colon Cancer Cells Cancer Res., September 1, 2002; 62(17): 4903 - 4908. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Weber, M. Lu, L. Andera, H. Lahm, N. Gellert, M. W. Fariss, V. Korinek, W. Sattler, D. S. Ucker, A. Terman, et al. Vitamin E Succinate Is a Potent Novel Antineoplastic Agent with High Selectivity and Cooperativity with Tumor Necrosis Factor-related Apoptosis-inducing Ligand (Apo2 Ligand) in Vivo Clin. Cancer Res., March 1, 2002; 8(3): 863 - 869. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Secchiero, A. Gonelli, C. Celeghini, P. Mirandola, L. Guidotti, G. Visani, S. Capitani, and G. Zauli Activation of the nitric oxide synthase pathway represents a key component of tumor necrosis factor-related apoptosis-inducing ligand-mediated cytotoxicity on hematologic malignancies Blood, October 1, 2001; 98(7): 2220 - 2228. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. M. Dirsch, H. Stuppner, and A. M. Vollmar Helenalin Triggers a CD95 Death Receptor-independent Apoptosis That Is Not Affected by Overexpression of Bcl-xL or Bcl-2 Cancer Res., August 1, 2001; 61(15): 5817 - 5823. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Jelachich and H. L. Lipton Theiler's Murine Encephalomyelitis Virus Induces Apoptosis in Gamma Interferon-Activated M1 Differentiated Myelomonocytic Cells through a Mechanism Involving Tumor Necrosis Factor Alpha (TNF-{alpha}) and TNF-{alpha}-Related Apoptosis-Inducing Ligand J. Virol., July 1, 2001; 75(13): 5930 - 5938. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Özören, K. Kim, T. F. Burns, D. T. Dicker, A. D. Moscioni, and W. S. El-Deiry The Caspase 9 Inhibitor Z-LEHD-FMK Protects Human Liver Cells while Permitting Death of Cancer Cells Exposed to Tumor Necrosis Factor-related Apoptosis-inducing Ligand Cancer Res., November 1, 2000; 60(22): 6259 - 6265. [Abstract] [Full Text] |
||||
![]() |
D. Bernard, B. Quatannens, B. Vandenbunder, and C. Abbadie Rel/NF-kappa B Transcription Factors Protect against Tumor Necrosis Factor (TNF)-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis by Up-regulating the TRAIL Decoy Receptor DcR1 J. Biol. Chem., July 13, 2001; 276(29): 27322 - 27328. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. F. Burns and W. S. El-Deiry Identification of Inhibitors of TRAIL-induced Death (ITIDs) in the TRAIL-sensitive Colon Carcinoma Cell Line SW480 Using a Genetic Approach J. Biol. Chem., October 5, 2001; 276(41): 37879 - 37886. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |